Moomoo AI 已提取核心信息
Adimab, LLC, a Delaware-based limited liability company, has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), reporting a significant transaction involving shares of Invivyd, Inc. The amendment, dated January 19, 2024, indicates that Adimab, LLC has sold 5,000,000 shares of Invivyd's common stock. The sale was executed under Rule 144 at a price of $3.95 per share. Following the sale, Adimab, LLC still beneficially owns 21,687,906 shares, representing 19.7% of Invivyd's class of common stock. This ownership percentage is based on the 110,114,960 shares of common stock outstanding as reported in Invivyd's Quarterly Report for the quarter ended September 30, 2023. The amendment also notes that the company, formerly known as Adagio Therapeutics, Inc., officially changed its name to Invivyd, Inc. on September 13, 2022, following the filing of a certificate of amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. No other transactions in Invivyd's common stock were reported by Adimab, LLC or related persons in the past 60 days.
Adimab, LLC, a Delaware-based limited liability company, has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), reporting a significant transaction involving shares of Invivyd, Inc. The amendment, dated January 19, 2024, indicates that Adimab, LLC has sold 5,000,000 shares of Invivyd's common stock. The sale was executed under Rule 144 at a price of $3.95 per share. Following the sale, Adimab, LLC still beneficially owns 21,687,906 shares, representing 19.7% of Invivyd's class of common stock. This ownership percentage is based on the 110,114,960 shares of common stock outstanding as reported in Invivyd's Quarterly Report for the quarter ended September 30, 2023. The amendment also notes that the company, formerly known as Adagio Therapeutics, Inc., officially changed its name to Invivyd, Inc. on September 13, 2022, following the filing of a certificate of amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. No other transactions in Invivyd's common stock were reported by Adimab, LLC or related persons in the past 60 days.
总部位于特拉华州的有限责任公司Adimab, LLC已向美国证券交易委员会（SEC）提交了其附表13D的修正案，报告了一笔涉及Invivyd, Inc.股票的重大交易。该修正案于2024年1月19日发布，表明Adimab, LLC已出售了Invivyd的500万股普通股。此次出售是根据规则144执行的，价格为每股3.95美元。出售后，Adimab, LLC仍实益拥有21,687,906股股票，占Invivyd普通股类别的19.7％。该所有权百分比基于Invivyd截至2023年9月30日的季度季度报告中公布的110,114,960股已发行普通股。该修正案还指出，该公司前身为Adagio Therapeutics, Inc.，在向特拉华州国务卿提交了经修订和重述的公司注册证书的修正证书后，于2022年9月13日正式更名为Invivyd, Inc.。在过去的60天中，Adimab, LLC或关联人员没有报告Invivyd普通股的其他交易。
总部位于特拉华州的有限责任公司Adimab, LLC已向美国证券交易委员会（SEC）提交了其附表13D的修正案，报告了一笔涉及Invivyd, Inc.股票的重大交易。该修正案于2024年1月19日发布，表明Adimab, LLC已出售了Invivyd的500万股普通股。此次出售是根据规则144执行的，价格为每股3.95美元。出售后，Adimab, LLC仍实益拥有21,687,906股股票，占Invivyd普通股类别的19.7％。该所有权百分比基于Invivyd截至2023年9月30日的季度季度报告中公布的110,114,960股已发行普通股。该修正案还指出，该公司前身为Adagio Therapeutics, Inc.，在向特拉华州国务卿提交了经修订和重述的公司注册证书的修正证书后，于2022年9月13日正式更名为Invivyd, Inc.。在过去的60天中，Adimab, LLC或关联人员没有报告Invivyd普通股的其他交易。
有用
没用